Boston Scientific to Announce Results from its TAXUS V Drug-Eluting Stent Clinical Trial, Studying Most Challenging Lesions and Highest-Risk Patients
(March 3, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the American College of Cardiology annual scientific session, which runs from March 6 to 9 in Orlando, Florida.
Sunday, March 6
TAXUS V Results.
At 10:15 a.m., the Company will release nine-month results from its TAXUS V clinical trial, which is assessing the safety and efficacy of its TAXUS® Express2
™ paclitaxel-eluting stent system. TAXUS V expands on the TAXUS IV pivotal trial by studying a higher-risk patient population, including patients with small vessels, large vessels and long lesions requiring multiple overlapping stents -- the most challenging lesions and highest-risk patients ever studied in a randomized controlled drug-eluting stent trial in the U.S. The results will be presented by Gregg W. Stone, M.D., the study's Principal Investigator, at a scientific session in Hall A of the Orange County Convention Center, 9800 International Drive, Orlando, at 10:15 a.m. The Company will also issue a press release at that time.
DES Educational Symposium.
At 7:30 p.m., the Company will host a symposium entitled, "TAXUS Stent - The New Evidence: Expanding the Frontier" in Ballroom G of the Rosen Centre Hotel, 9840 International Drive, Orlando. The Company will host a reception prior to the symposium from 7:00 to 7:30 p.m. outside Ballroom G.
Monday, March 7
At 7:30 a.m., the Company will host an analyst meeting in the Grand Ballroom of the Rosen Centre Hotel. The meeting is open to the media. This meeting is being webcast and can be accessed at Boston Scientific's website, www.bostonscientific.com. Please visit the website beginning March 6 for details on how to access the webcast. To ensure a timely connection to the webcast it is recommended that users register at least 15 minutes before the webcast begins. A replay of the webcast will be archived and available for 10 business days in the Webcast and Archives section of the Investor Relations site at www.bostonscientific.com beginning at approximately 1:00 p.m. ET on March 7 and running through Tuesday, March 22.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.